NEWS! NioCorp Announces Up To $16.5 Million Private

New Post Public Reply Private Reply Replies (0) Message Board
Sawbuckle
NEWS!

NioCorp Announces Up To $16.5 Million Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 22, 2014) -

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES

NioCorp Developments Ltd. ("NioCorp" or the "Company" (TSX VENTURE:NB)(OTCQX:NIOBF)(FRANKFURT:BR3) is pleased to announce that it has entered into an agreement with Mackie Research Capital Corporation (the "Agent" in connection with a private placement of special warrants (the "Special Warrants" to raise aggregate gross proceeds of up to $16.5 million, at an issue price to be determined in the context of the market (the "Offering". The Offering will be conducted on a "best efforts" private placement basis.

Each Special Warrant will be exchangeable at any time after the closing date of the Offering for no additional consideration into one unit of the Company (a "Unit". Each Unit will consist of one common share of the Company (a "Common Share" and one common share purchase warrant (a "Warrant". Each Warrant will entitle the holder thereof to acquire one additional Common Share (a "Warrant Share" at a price to be determined in the context of the market for up to twenty-four (24) months from closing date of the Offering.

The Company has also granted the Agent an option (the "Agent's Option" to increase the size of the Offering by up to 15% in Special Warrants, by giving written notice of the exercise of the Agent's Option, or a part thereof, to the Company at any time up to 48 hours prior to the closing date of the Offering.

The net proceeds from the Offering will be used by the Company for continued development of NioCorp's Elk Creek niobium project, including, but not limited to, ongoing drilling, metallurgical studies including pilot plant work and detailed engineering ahead of a feasibility study, and for general corporate purposes.

The Company advises that senior management intend to subscribe for approximately $2.5 million of the Offering.

The Offering will take place by way of a private placement to qualified investors in such provinces of Canada (except Quebec) as the Agents may designate, and otherwise in those jurisdictions where the Offering can lawfully be made, including the United States and Europe under applicable private placement exemptions.

The Company will as soon as reasonably practicable after the Closing, obtain a receipt for a final short form prospectus of the Company filed pursuant to National Policy 11-202 and Multilateral Instrument 11-102, issued by the securities regulators in such jurisdictions in Canada in which a holder of Special Warrants is resident (collectively, the "Liquidity Event". In the event that the Liquidity Event does not occur within 75 days following the closing date of the Offering, each unexercised Special Warrant, including the Special Warrants offered as part of the Agents' Option and the Compensation Options (defined below), will thereafter entitle the holder thereof to receive upon the automatic exercise thereof, at no additional consideration, 1.10 Units (instead of one Unit). Unless qualified by a (final) prospectus, the securities to be issued under the Offering will be subject to a four month and one day hold period.

All unexercised Special Warrants will be deemed to be exercised on the earlier of (i) the date which is four months and one day following the closing date of the Offering, and (ii) the 3rd business day after the occurrence of a Liquidity Event.

The Closing is expected on or about the week of October 15th, 2014 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals including the approval of the TSX Venture Exchange.

In consideration for their services, the Agent will receive a cash commission equal to 6.5% of the gross proceeds of the Offering and non-transferable compensation options (the "Compensation Options" equal to 6.5% of the Special Warrants issued pursuant to the Offering. Each Compensation Option shall entitle the Agent to purchase a Special Warrant at the offering price of the Special Warrants.

About the Company: NioCorp is developing the only primary niobium deposit known to be under development in the U.S., and the highest grade undeveloped niobium deposit in North America, located near Elk Creek, Nebraska. The Company has published an NI 43-101 resource report, which is available on SEDAR or the Company's website. An updated NI 43-101 resource report is currently being prepared for filing. Niobium is mainly used in the form of Ferro-Niobium to produce HSLA (High Strength, Low Alloy) steel, to produce lighter, stronger steel for use in automotive, structural and pipeline industries. The U.S. imports 100% of its niobium needs.

About Mackie Research Capital Corporation: Mackie Research Capital is one of Canada's largest independent full service investment firms, and proudly traces its roots back to 1921. We are privately owned by many of our 350 employees. As a fully integrated national investment dealer, we offer a full complement of capital markets and wealth management services to private and institutional clients and growth companies.

For more information about Mackie Research Capital Corporation, please visit www.mackieresearch.com.

NioCorp Developments Ltd. (NIOBD) Stock Research Links

NIOBD Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LIV Golf's Big Play: Restructuring with Saudi PIF

Updated Category News Views 6

Trailblazing Change in the Golf World It's like watching a high-stakes game of chess where pieces are worth billions. White Knight Capital Corp. has thrown its hat into the ring with the Public Investment Fund of Saudi Arabia to overhaul LIV Golf Enterprises. This isn't your average Monday morning golf chat; it's full-on corporate drama with financial steroids. Debt Swap...

Continue Reading
Innovative SOV Launches for Offshore Wind Revolution

Updated Category News Views 2

A New Era for Offshore Wind Operations Mark my words, folks, this launch ain't just some minor milestone swaying gently on the industry seas. ZPMC's 'Wind of Ocean' is about to kickstart a whole new game in Europe's offshore wind space. Built with brains and brawn, this vessel embodies the future of sustainable and efficient offshore operations. The announcement from...

Continue Reading
MiniTool MovieMaker 8.9: Keyframe Animation Upgrade

Updated Category News Views 2

Breaking Down MiniTool MovieMaker 8.9's Revamp Kicking off the day with some noteworthy news in the creative software arena, MiniTool's latest update to its MovieMaker program is grabbing attention. It’s not often you hear software developers hitting the right balance between functionality and simplicity as they've done with this release. Keyframe Animation: The Star of...

Continue Reading
Fujifilm's New 400mm Lens: A Game Changer?

Updated Category News Views 1

Big Moves from Fujifilm's Camp Now we're talking, Fujifilm! Just when you think they might ease off the throttle, they crank up the heat with the XF 400mm f/4.5 R LM OIS WR lens. This isn’t just your run-of-the-mill update. It's a significant addition to their already beefed-up lineup for sports and wildlife. You know what that means: more reach, less baggage. Compact...

Continue Reading
Argo Biopharma's BW-20805 Shows Promise in HAE Phase II Trial

Updated Category News Views 1

Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...

Continue Reading
Clinical Trials Services Market Set for Big Growth

Updated Category News Views 2

Eyeing a Market Surge in Clinical Trials Numbers don't lie, and they're painting a promising picture for the clinical trials services market with a solid 8% growth forecasted annually till 2031. From a modest $66.20 billion in 2026, we're looking at ballooning to a hefty $97.41 billion by 2031. What’s cooking? Let me dish it out for you. Key Drivers and Dynamics North...

Continue Reading
Potomac Edison Eyes Rate Hike for System Overhaul

Updated Category News Views 0

FirstEnergy's Potomac Edison Pushes for Rate Adjustment The walls are closing in on the energy sector, and Potomac Edison is seizing the moment. With their proposed $52.8 million rate adjustment, they're not only aiming to keep the lights on but to power up their entire infrastructure game. It's a gutsy move, particularly in volatile times. The Price Tag: Weighing Costs...

Continue Reading
Pathlock Faces Identity Governance Opportunities in 2026

Updated Category News Views 3

Challenges in Identity Governance Emerge for 2026 Imagine a world where digital identities run wild—unmonitored, orphaned, dormant. Welcome to 2026, where identity governance and administration (IGA) face a reckoning, dragging enterprises into the spotlight as they scramble to protect against identity chaos. With Pathlock’s recent recognition in the Gartner Market...

Continue Reading
Reolink Unveils OMVI 2i Ultra at IFA 2026

Updated Category News Views 6

Reolink's Bold Move Into the Future of Home Security Amidst the hustle of Berlin's IFA 2026, Reolink dropped its latest gem: the OMVI 2i Ultra—an all-in-one security powerhouse promising to change the game for home protection junkies. As usual, Reolink's got its eyes on the prize, pushing boundaries with this latest lineup. OMVI 2i Ultra: Dual-View Revolution If you've...

Continue Reading
China's Diplomatic Dance: SCO Summit & Key Visits

Updated Category News Views 2

A Diplomatic Balancing Act Xi Jinping's recent diplomatic tour, climaxing at the Shanghai Cooperation Organization (SCO) Summit and extending through critical visits to Kyrgyzstan and Egypt, paints a compelling picture of China's strategic intentions. For those of us watching the geopolitical chessboard, it's like seeing a master strategist at work—pondering a tricky...

Continue Reading

Top 5 Most Recently Viewed Articles

Theravance Buyout Scrutinized: Is Zymeworks Deal Fair?

Updated Category News Views 6

Theravance and Zymeworks: What's the Deal? First things first, the numbers. Theravance Biopharma, the biotech entity waving its NASDAQ: TBPH ticker, is about to jump into bed with Zymeworks, another player in the pharma game. The pitch? One hundred seventy-six bucks a share in cold, hard cash, plus a contingent value right. That's right—sweet on paper, but always worth...

Continue Reading
Top Stock Split Opportunities for Maximum Growth Potential

Updated Category News Views 72

Stock splits surged back into the limelight recently, flipping the script on a strategy that had been gathering dust. Once thought outdated, these moves have become hot again, reflecting how companies with robust performances can maintain investor interest while managing share prices effectively. When you see a stock split, it’s often more than just a number game; it's...

Continue Reading
Roc Nation and Musicow: Pioneering a New Era in Music Equity

Updated Category News Views 455

Roc Nation Collaborates with Musicow for Music Equity Innovation Roc Nation has embarked on an exciting partnership with Musicow, a South Korean fintech firm. This collaboration aims to introduce the first Music Equity Service Provider (MESP) in the United States. By allowing music rights holders to buy, sell, and trade shares in music royalty revenue, this initiative...

Continue Reading
Latest Updates from the FDA: New Guidelines and Approvals

Updated Category News Views 396

Insights from Recent FDA Activities The U.S. Food and Drug Administration (FDA) has released an overview of recent important developments aimed at enhancing public health and safety. These updates offer invaluable information about various health issues, product approvals, and guidance to manufacturers. Investigation of E. coli Outbreak Recently, the FDA updated its...

Continue Reading
Insider Sale Sparks Interest in BorgWarner's Future Prospects

Updated Category News Views 173

Understanding Insider Transactions at BorgWarner Recently, a notable insider sale captured attention. Isabelle McKenzie, the Vice President of BorgWarner, made headlines when she sold 2,500 shares, totaling around $100,025. This transaction was officially reported in a filing to the SEC, particularly through a Form 4. Such insider activities often spark curiosity among...

Continue Reading